Varian Creates Patient Education Web Site

How Supportive Care Methods Can Improve Oncology Outcomes

Data from a phase 1/2 trial demonstrate the potential antitumor activity of FOG-001 in patients with desmoid tumors.

Experts discussed supportive care and why it should be integrated into standard oncology care.

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD

November 10th 2025

FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications

Experts discussed supportive care and why it should be integrated into standard oncology care.

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.

Tim Cortese

What Were The Most Impactful GU Oncology Data From ESMO 2025?

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

November 6th 2025

Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Ariana Pelosci

November 12th 2025

FOG-001 Earns FDA Fast Track Designation in Desmoid Tumors

DFS rates at 2 years were improved with cemiplimab plus SBRT vs cemiplimab alone in patients with resectable hepatocellular carcinoma.

Related Content

How Supportive Care Methods Can Improve Oncology Outcomes

Data from a phase 1/2 trial demonstrate the potential antitumor activity of FOG-001 in patients with desmoid tumors.

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD

November 10th 2025

FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications

Experts discussed supportive care and why it should be integrated into standard oncology care.

Tim Cortese

What Were The Most Impactful GU Oncology Data From ESMO 2025?

The FDA has approved pertuzumab-dpzb (Poherdy) as a biosimilar to pertuzumab (Perjeta) in breast cancer, based on a review of various attributes, including safety and efficacy data.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

November 6th 2025

Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Neoadjuvant Cemiplimab/SBRT Yields Improved DFS in Resectable HCC

Data from a phase 1 trial demonstrate the safety and feasibility of administering chlorotoxin-based cellular therapy to those with recurrent glioblastoma.

Ariana Pelosci

November 12th 2025